267 related articles for article (PubMed ID: 14592887)
1. T cells and cytokines in the pathogenesis of acquired myasthenia gravis.
Milani M; Ostlie N; Wang W; Conti-Fine BM
Ann N Y Acad Sci; 2003 Sep; 998():284-307. PubMed ID: 14592887
[TBL] [Abstract][Full Text] [Related]
2. Animal models of myasthenia gravis.
Christadoss P; Poussin M; Deng C
Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
[TBL] [Abstract][Full Text] [Related]
3. Transgenic expression of IL-10 in T cells facilitates development of experimental myasthenia gravis.
Ostlie NS; Karachunski PI; Wang W; Monfardini C; Kronenberg M; Conti-Fine BM
J Immunol; 2001 Apr; 166(8):4853-62. PubMed ID: 11290761
[TBL] [Abstract][Full Text] [Related]
4. The susceptibility to experimental myasthenia gravis of STAT6-/- and STAT4-/- BALB/c mice suggests a pathogenic role of Th1 cells.
Wang W; Ostlie NS; Conti-Fine BM; Milani M
J Immunol; 2004 Jan; 172(1):97-103. PubMed ID: 14688314
[TBL] [Abstract][Full Text] [Related]
5. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice.
Karachunski PI; Ostlie NS; Monfardini C; Conti-Fine BM
J Immunol; 2000 May; 164(10):5236-44. PubMed ID: 10799884
[TBL] [Abstract][Full Text] [Related]
6. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis.
Wang HB; Shi FD; Li H; van der Meide PH; Ljunggren HG; Link H
Clin Immunol; 2000 May; 95(2):156-62. PubMed ID: 10779409
[TBL] [Abstract][Full Text] [Related]
7. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.
Wang W; Milani M; Ostlie N; Okita D; Agarwal RK; Caspi RR; Conti-Fine BM
J Immunol; 2007 Jun; 178(11):7072-80. PubMed ID: 17513756
[TBL] [Abstract][Full Text] [Related]
8. Cytokines and the pathogenesis of myasthenia gravis.
Zhang GX; Navikas V; Link H
Muscle Nerve; 1997 May; 20(5):543-51. PubMed ID: 9140360
[TBL] [Abstract][Full Text] [Related]
9. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
[TBL] [Abstract][Full Text] [Related]
10. Novel animal models of acetylcholine receptor antibody-related myasthenia gravis.
Tüzün E; Allman W; Ulusoy C; Yang H; Christadoss P
Ann N Y Acad Sci; 2012 Dec; 1274():133-9. PubMed ID: 23252908
[TBL] [Abstract][Full Text] [Related]
11. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
Baggi F; Antozzi C; Toscani C; Cordiglieri C
Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
[TBL] [Abstract][Full Text] [Related]
12. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice.
Balasa B; Deng C; Lee J; Bradley LM; Dalton DK; Christadoss P; Sarvetnick N
J Exp Med; 1997 Aug; 186(3):385-91. PubMed ID: 9236190
[TBL] [Abstract][Full Text] [Related]
13. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis.
Balasa B; Deng C; Lee J; Christadoss P; Sarvetnick N
J Immunol; 1998 Sep; 161(6):2856-62. PubMed ID: 9743346
[TBL] [Abstract][Full Text] [Related]
14. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis.
Wang HB; Li H; Shi FD; Chambers BJ; Link H; Ljunggren HG
Int Immunol; 2000 Oct; 12(10):1381-8. PubMed ID: 11007755
[TBL] [Abstract][Full Text] [Related]
16. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
[TBL] [Abstract][Full Text] [Related]
17. Ocular myasthenia gravis induced by human acetylcholine receptor ϵ subunit immunization in HLA DR3 transgenic mice.
Wu X; Tuzun E; Saini SS; Wang J; Li J; Aguilera-Aguirre L; Huda R; Christadoss P
Immunol Lett; 2015 Dec; 168(2):306-12. PubMed ID: 26493475
[TBL] [Abstract][Full Text] [Related]
18. Complement and cytokine based therapeutic strategies in myasthenia gravis.
Tüzün E; Huda R; Christadoss P
J Autoimmun; 2011 Sep; 37(2):136-43. PubMed ID: 21636248
[TBL] [Abstract][Full Text] [Related]
19. CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis.
Conti-Fine BM; Milani M; Wang W
Ann N Y Acad Sci; 2008; 1132():193-209. PubMed ID: 18567869
[TBL] [Abstract][Full Text] [Related]
20. T-bet deficiency decreases susceptibility to experimental myasthenia gravis.
Liu R; Hao J; Dayao CS; Shi FD; Campagnolo DI
Exp Neurol; 2009 Dec; 220(2):366-73. PubMed ID: 19818352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]